Get the Stockscreener App
15.85
0.19%
-0.03
Aurinia Pharmaceuticals Inc stock is traded at $15.85, with a volume of 959.51K.
It is down -0.19% in the last 24 hours and up +1.99% over the past month.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
See More
Previous Close:
$15.88
Open:
$15.98
24h Volume:
959.51K
Relative Volume:
0.58
Market Cap:
$2.09B
Revenue:
$260.11M
Net Income/Loss:
$60.64M
P/E Ratio:
36.86
EPS:
0.43
Net Cash Flow:
$92.29M
1W Performance:
+1.47%
1M Performance:
+1.99%
6M Performance:
+92.59%
1Y Performance:
+63.57%
1-Day Range:
$15.71
$15.99
1-Week Range:
$15.15
$16.03
52-Week Range:
$6.55
$16.48
Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile
Name
Aurinia Pharmaceuticals Inc
Sector
Industry
Phone
250-744-2487
Address
#140, 14315 - 118 AVENUE, EDMONTON, BC
Compare AUPH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AUPH
Aurinia Pharmaceuticals Inc
|
15.85 | 2.09B | 260.11M | 60.64M | 92.29M | 0.43 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-03-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Nov-07-25 | Upgrade | Jefferies | Hold → Buy |
| Nov-05-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-30-25 | Resumed | H.C. Wainwright | Buy |
| Nov-04-22 | Downgrade | Oppenheimer | Outperform → Perform |
| May-05-22 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-10-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-28-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-25-21 | Reiterated | H.C. Wainwright | Buy |
| Nov-03-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| May-05-20 | Initiated | Cowen | Outperform |
| Jan-10-20 | Initiated | Jefferies | Buy |
| Dec-16-19 | Reiterated | H.C. Wainwright | Buy |
| Mar-16-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Feb-08-18 | Initiated | RBC Capital Mkts | Outperform |
| Oct-30-17 | Reiterated | H.C. Wainwright | Buy |
| May-18-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-11-17 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-22-17 | Reiterated | FBR & Co. | Outperform |
| Dec-30-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-17-16 | Reiterated | H.C. Wainwright | Buy |
| Jun-30-16 | Initiated | H.C. Wainwright | Buy |
| May-08-15 | Initiated | MLV & Co | Buy |
View All
Aurinia Pharmaceuticals Inc Stock (AUPH) Latest News
How (AUPH) Movements Inform Risk Allocation Models - news.stocktradersdaily.com
Aruinia discloses FDA information request on Lupkynis amid top regulator’s exit - MSN
Aurinia Pharmaceuticals Inc $AUPH Shares Purchased by Jump Financial LLC - MarketBeat
Are Medical Stocks Lagging Aurinia Pharmaceuticals (AUPH) This Year? - Yahoo Finance
Earnings Report: Can Aurinia Pharmaceuticals Inc stock deliver 10 annual returns2025 AllTime Highs & Long-Term Safe Investment Ideas - moha.gov.vn
State Board of Administration of Florida Retirement System Has $1.22 Million Stock Position in Aurinia Pharmaceuticals Inc $AUPH - MarketBeat
Schroder Investment Management Group Has $4.64 Million Holdings in Aurinia Pharmaceuticals Inc $AUPH - MarketBeat
What Makes Aurinia Pharmaceuticals (AUPH) a Strong Momentum Stock: Buy Now? - sharewise.com
Will Aurinia Pharmaceuticals Inc. (IKAP) stock return to pre crash levelsWeekly Trade Report & Low Risk Entry Point Guides - Newser
Can Aurinia Pharmaceuticals Inc. stock weather global recessionWeekly Trade Review & Detailed Earnings Play Alerts - Newser
How Aurinia Pharmaceuticals Inc. (IKAP) stock valuation compares with sectorJuly 2025 Action & High Accuracy Trade Signal Alerts - Newser
Aurinia Pharmaceuticals (NASDAQ:AUPH) Shares Down 5.2%Time to Sell? - MarketBeat
Aurinia Pharmaceuticals (NASDAQ:AUPH) Lowered to Hold Rating by Leerink Partnrs - MarketBeat
Can Aurinia Pharmaceuticals Inc. stock surprise with earnings upsideStock Surge & Reliable Price Breakout Signals - Newser
Aurinia Pharmaceuticals Shares Fall After Leerink Partners Downgrade - marketscreener.com
Aurinia Pharmaceuticals (NASDAQ:AUPH) Shareholders Have Earned a 51% CAGR Over the Last Three Years - 富途牛牛
Leerink Partners downgrades Aurinia Pharmaceuticals stock rating on growth concerns - Investing.com Canada
Leerink Partners Downgrades Aurinia Pharmaceuticals to Market Perform From Outperform, Adjusts PT to $16 From $15 - marketscreener.com
Will Aurinia Pharmaceuticals Inc. stock sustain high P E ratios2025 Dividend Review & Fast Momentum Stock Entry Tips - Newser
Defamation Litigation Roundup: FDA, Lively, Alexander Bros. - Law360
Aurinia Raises Guidance and Shares Are Surging— Is This Why a Major Investor Just Boosted Its Stake? - Yahoo Finance
Trading Systems Reacting to (AUPH) Volatility - news.stocktradersdaily.com
Implied Volatility Surging for Aurinia Pharmaceuticals Stock Options - sharewise.com
Will Aurinia Pharmaceuticals Inc. (IKAP) stock test record highs in 2025Analyst Downgrade & Weekly Setup with ROI Potential - Newser
Aurinia Pharmaceuticals Inc $AUPH Stake Trimmed by Geode Capital Management LLC - MarketBeat
What earnings margins imply for Aurinia Pharmaceuticals Inc. (IKAP) stock2025 Technical Overview & Low Drawdown Trading Strategies - Newser
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Is Aurinia Pharmaceuticals Still a Good Value After 83.8% YTD Surge? - Yahoo Finance
A Look at Aurinia Pharmaceuticals (NasdaqGM:AUPH) Valuation After Recent Share Price Surge - Yahoo Finance
Virtus Investment Advisers LLC Has $457,000 Stake in Aurinia Pharmaceuticals Inc $AUPH - MarketBeat
How Aurinia Pharmaceuticals Inc. (IKAP) stock trades pre earningsEarnings Performance Report & Trade Opportunity Analysis - BỘ NỘI VỤ
Why retail investors favor Aurinia Pharmaceuticals Inc. stockJuly 2025 Review & Community Driven Trade Alerts - moha.gov.vn
Advantage Alpha Capital Partners LP Takes $204,000 Position in Aurinia Pharmaceuticals Inc $AUPH - MarketBeat
Segall Bryant & Hamill LLC Sells 221,933 Shares of Aurinia Pharmaceuticals Inc $AUPH - MarketBeat
Rigel Pharmaceuticals, Inc. (RIGL) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance
Aurinia Pharmaceuticals Inc $AUPH Shares Bought by SG Americas Securities LLC - MarketBeat
Aurinia Pharmaceuticals (NASDAQ:AUPH) Reaches New 12-Month HighHere's Why - MarketBeat
Is Aurinia Pharmaceuticals (AUPH) Stock Outpacing Its Medical Peers This Year? - sharewise.com
[Form 4] Aurinia Pharmaceuticals Inc. Insider Trading Activity - Stock Titan
Dir Bailey Surrenders 2,716 Of Aurinia Pharmaceuticals Inc [AUPH] - TradingView
Aurinia Pharmaceuticals Inc. (IKAP.F) stock price, news, quote and history - Yahoo Finance UK
Aurinia Pharmaceuticals stock hits 52-week high at $16.20 By Investing.com - Investing.com Nigeria
Aurinia Pharmaceuticals stock hits 52-week high at $16.20 - Investing.com India
First Week of AUPH July 2026 Options Trading - Nasdaq
Are Options Traders Betting on a Big Move in Aurinia Pharmaceuticals (AUPH) Stock? - MSN
Is Aurinia Pharmaceuticals Inc. stock positioned for long term growthWeekly Trend Recap & Free Weekly Watchlist of Top Performers - newser.com
Aurinia Delivers Growth While Balancing Biotech Risks - Finimize
Aurinia Pharmaceuticals Inc Stock (AUPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aurinia Pharmaceuticals Inc Stock (AUPH) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| TANG KEVIN | Director |
Aug 05 '25 |
Buy |
11.68 |
200,000 |
2,336,000 |
11,329,500 |
| TANG KEVIN | Director |
Aug 04 '25 |
Buy |
11.34 |
100,000 |
1,134,000 |
11,129,500 |
| Keenan Greg | Chief Medical Officer |
Aug 01 '25 |
Sale |
10.50 |
20,000 |
210,000 |
133,484 |
| Keenan Greg | Chief Medical Officer |
Mar 07 '25 |
Sale |
8.23 |
8,305 |
68,350 |
153,484 |
| Greenleaf Peter | Chief Executive Officer |
Mar 03 '25 |
Sale |
8.00 |
195,593 |
1,564,744 |
1,953,892 |
| Greenleaf Peter | Chief Executive Officer |
Mar 04 '25 |
Sale |
7.92 |
164,947 |
1,306,380 |
1,788,945 |
| Keenan Greg | Chief Medical Officer |
Mar 03 '25 |
Sale |
8.00 |
12,239 |
97,912 |
161,789 |
| Miller Joseph M | Chief Financial Officer |
Mar 03 '25 |
Sale |
8.00 |
61,859 |
494,872 |
633,515 |
| Miller Joseph M | Chief Financial Officer |
Mar 04 '25 |
Sale |
7.92 |
56,154 |
444,740 |
577,361 |
| Robertson Stephen P. | EVP, General Counsel |
Mar 03 '25 |
Sale |
8.00 |
64,872 |
518,976 |
566,883 |
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):